title: Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.
abstract: Sequential endocrine therapy (ET) is recommended for postmenopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and without visceral symptoms. Chemotherapy (CT) can be considered after sequential ETs, but is associated with adverse side effects. We assessed physicians' preferences and self-reported prescribing patterns for ET and CT in the treatment of HR+/HER2- mBC at community practices in the United States. Community-based oncologists/hematologists from a nationwide online panel who treated postmenopausal women with HR+/HER2- mBC were invited to complete a survey, blinded to the identity of study sponsor. Treatment preferences were collected by treatment class of ET-based regimens versus CT and by agent for postmenopausal HR+/HER2- mBC patients after prior nonsteroidal aromatase inhibitor use in the adjuvant or mBC setting. Among 213 physicians who completed the survey, 78% were male, 71% were based in small/intermediate practices (2-9 oncologists/subspecialists), 55% had >10 years of experience, and 58% referred to the National Comprehensive Cancer Network Guidelines when treating mBC. Among first-line ETs, anastrozole was the most frequently used treatment (35%), followed by everolimus-based (EVE, 34%) and fulvestrant-based (FUL, 15%) therapy. After first-line ET, the most preferred second- and third-line treatments were ET monotherapy (48% and 39%), ET combination therapy (31% and 19%), and CT monotherapy (13% and 30%). Comparing EVE versus FUL, physicians preferred EVE in all lines but first line. Efficacy was the most important consideration for treatment choice. Physicians prescribed CT in early lines mainly because of visceral symptoms. This survey of treatment patterns for HR+/HER2- mBC in community practice suggested that after first-line ET, ET mono- or combination therapy was commonly used for the second- and third-line treatments and CT monotherapy for third- or later line treatments. CTs were used in early lines for patients with visceral symptoms.
authors.affiliation: Analysis Group, Inc., Boston, Massachusetts.
authors.forename: Peggy L
authors.initials: PL
authors.lastname: Lin
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
authors.forename: Yanni
authors.initials: Y
authors.lastname: Hao
authors.affiliation: Analysis Group, Inc., New York, New York.
authors.forename: Jipan
authors.initials: J
authors.lastname: Xie
authors.affiliation: Analysis Group, Inc., Boston, Massachusetts.
authors.forename: Nanxin
authors.initials: N
authors.lastname: Li
authors.affiliation: Analysis Group, Inc., Boston, Massachusetts.
authors.forename: Yichen
authors.initials: Y
authors.lastname: Zhong
authors.affiliation: Analysis Group, Inc., Boston, Massachusetts.
authors.forename: Zhou
authors.initials: Z
authors.lastname: Zhou
authors.affiliation: Analysis Group, Inc., Boston, Massachusetts.
authors.forename: James E
authors.initials: JE
authors.lastname: Signorovitch
authors.affiliation: Analysis Group, Inc., Boston, Massachusetts.
authors.forename: Eric Q
authors.initials: EQ
authors.lastname: Wu
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D011307:Drug Prescriptions; D005260:Female; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010820:Physicians; D017698:Postmenopause; D010818:Practice Patterns, Physicians'; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012307:Risk Factors; D011795:Surveys and Questionnaires; D014481:United States / Q000453:epidemiology
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
keywords: Chemotherapy; endocrine therapy; everolimus; fulvestrant; metastatic breast cancer; survey